WALTHAM, Mass. -- (BUSINESS WIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on management of chronic pain and peripheral neuropathies, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw Annual Global Investment Conference at the Millennium Broadway Hotel, New York, NY on September 8-10, 2013. Dr. Gozani intends to provide an update on the Company’s business activities including the SENSUS™ Pain Management System, which is an electrical nerve stimulator uniquely designed for controlling chronic pain caused by diabetic neuropathy.
NeuroMetrix's presentation is scheduled for Monday, September 9, 2013 at 2:50 pm (Eastern Daylight Time) in Room 7.03, 7th Floor. A live audio webcast will be available on the investor relations section of the corporate website - www.neurometrix.com. This webcast will be archived after the live event.
NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain and peripheral neuropathies. The Company is presently focused on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company also markets the DPNCheck® device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit http://www.neurometrix.com.